Evidence map›Paper›PMID 32039762›Full record

ArticleeLife2020

c-Maf restrains T-bet-driven programming of CCR6-negative group 3 innate lymphoid cells.

Caroline Tizian, Annette Lahmann, Oliver Hölsken, Catalina Cosovanu, Michael Kofoed-Branzk, Frederik Heinrich, Mir-Farzin Mashreghi, Andrey Kruglov, Andreas Diefenbach, Christian Neumann

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Group 3 innate lymphoid cells in intestinal health and disease.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Blimp-1 and c-Maf regulateWellcome open research · 2023
    Article
  12. Transcriptional control of ILC identity.Frontiers in immunology · 2023
    Review
  13. ILC3: a case of conflicted identity.Frontiers in immunology · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Innate lymphoid cells and cancer.Nature immunology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Caroline Tizian *Laboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Annette Lahmann *Chronic Immune Reactions, Deutsches Rheuma-Forschungszentrum, Berlin, Germany.
Oliver HölskenLaboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-6086-9275
Catalina CosovanuLaboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Michael Kofoed-BranzkLaboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Frederik HeinrichTherapeutic Gene Regulation, Deutsches Rheuma-Forschungszentrum, Berlin, Germany.
Mir-Farzin MashreghiTherapeutic Gene Regulation, Deutsches Rheuma-Forschungszentrum, Berlin, Germany.ORCID 0000-0002-8015-6907
Andrey KruglovChronic Inflammation, Deutsches Rheuma-Forschungszentrum, Berlin, Germany.
Andreas DiefenbachLaboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Christian NeumannLaboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-2202-1876
German Rheumatism Research Centre · DELomonosov Moscow State University · RU

Funding

Deutsche Forschungsgemeinschaft Priority Program 1937 "Innate Lymphoid Cells"Deutsche Forschungsgemeinschaft Priority Program 1937 "Innate Lymphoid Cells"European Regional Development Fund EFRE 1.8/11European Regional Development Fund ERDF 2014-2020
6 · The paper itself

Abstract

RORγt

Indexed as

Immunity, InnateAnimalsCell LineageCellular ReprogrammingInterleukin-18Interleukin-1betaLymphocytesMiceMice, Inbred C57BLNF-kappa BPromoter Regions, GeneticProto-Oncogene Proteins c-mafReceptors, CCR6Receptors, NotchSignal TransductionT-bet Transcription FactorCCR6 protein, mouseIL1B protein, mouseInterleukin-18Interleukin-1betaMaf protein, mouseNF-kappa BProto-Oncogene Proteins c-mafReceptors, CCR6Receptors, NotchT-bet Transcription FactorT-Box Domain ProteinsILC3 plasticityimmunologyinflammationinnate lymphoid cellsmousetranscriptional regulation

Identifiers

PMID32039762
PMCPMC7025824
OpenAlexW3005331653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.